Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male subjects with type 1 diabetes mellitus (T1DM) for at least 1 year, diagnostic criteria as defined by the American Diabetes Association~* Treated with insulin for T1DM for at least 1 year and with stable insulin treatment (defined as no more than a 10-unit daily variation in total daily insulin dose) 30 days prior to screening~* Hemoglobin A1c \<10%~Exclusion Criteria:~* Previously treated with dasiglucagon (previously referred to as ZP4207)~* Known or suspected allergy to trial product(s) or related products~* Females who are pregnant according to a positive pregnancy test, are actively attempting to get pregnant, or are lactating.~* History of hypoglycemic events associated with seizures in the last year prior to screening~* History of severe hypoglycemia in the last month prior to screening~* Active malignancy within the last 5 years~* Current bleeding disorder, including anti-coagulant treatment~* Known presence or history of pheochromocytoma (i.e. adrenal gland tumor) or insulinoma (i.e. insulin secreting pancreas tumor)~* Use of a daily systemic beta-blocker drug, indomethacin, warfarin or anticholinergic drugs in the previous 28 days before Day 1 of this trial~* Clinically significant abnormal ECG at screening as judged by the investigator~* Donation of blood or plasma in the past month, or in excess of 500 mL within 12 weeks prior to screening~* Surgery or trauma with significant blood loss within the last 2 months prior to screening~* A positive result in the alcohol and/or urine drug screen at the screening visit. Significant history of alcoholism or drug abuse as judged by the investigator or consuming more than 24 g alcohol per day for men, or more than 12 g alcohol per day for women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Dasiglucagon (Type: EXPERIMENTAL): Single fixed dose (s.c.injection) of dasiglucagon
- Placebo (Type: PLACEBO_COMPARATOR): Single fixed dose (s.c.injection) of placebo
- GlucaGen® (Type: ACTIVE_COMPARATOR): Single fixed dose (s.c.injection) of GlucaGen®

Based on this trial design, predict the completion outcome and termination type (if applicable).